Filing Details
Protara Therapeutics, Inc. (NASDAQ:TARA) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
8k filedNASDAQ:TARA
Protara Therapeutics, Inc. (TARA) Reports Material Event to SEC
Protara Therapeutics, Inc. (NASDAQ:TARA) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
At publication ·
What changed
Protara Therapeutics, Inc. (NASDAQ:TARA) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Protara Therapeutics, Inc. (NASDAQ: TARA) filed a Form 8-K with the SEC on August 11, 2026, disclosing a material event that shareholders should be aware of.
- The company's stock trades at $3.91 with a market capitalization of $231.5 million.
- The article does not specify the nature of the material event, which could involve leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance.
Market Context
Protara Therapeutics, Inc.'s stock currently trades at $3.91 with a market capitalization of $231.5M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Protara Therapeutics, Inc.'s stock.
All SEC filings for Protara Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View TARA Stock Page
Frequently Asked Questions
Where can I read TARA's SEC filings?
Browse all filings on our TARA SEC filings page.
What types of SEC filings does Protara Therapeutics, Inc. file?
Public companies like Protara Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.